First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research ...

CellFE, a leader in microfluidics-based cell engineering, and Made Scientific, a leading cell therapy contract development and manufacturing organization (CDMO), today announced a strategic ...

Financially, Creative Medical has limited cash reserves, high cash burn, and will likely need dilutive financing. Click here ...

The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor ...

The difference comes from the sourcing of raw materials and the functioning – and even nature – of supply chains. Because the ...

This is in the range of response rates we get with autologous ... allogeneic CAR T cells, we can get started right away with the lymphodepleting chemotherapy and be administering the treatment ...

The CardiAMP-HF trial of the autologous bone marrow mononuclear cell therapy (CardiAMP ... they’re not sensitized by allogeneic cells.” The primary outcome was a hierarchical composite ...

Cell therapy is ... two basic categories: autologous cell therapies, which involve removing a patient’s cells, modifying them, and returning them to the body, and allogeneic cell therapies ...

Korean cell and gene therapy firms seek global growth amid market challenges Korean biotechnology companies explore international opportunities despite recent setbacks ...